The firm maintains a robust liquidity profile with $54.5 million in cash and minimal debt of $282.4K as of 2026Q1, providing strategic flexibility despite accumulated deficits of $139.6 million.
Context Therapeutics Inc. (CNTX) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 45.82M | 68.35M | 97.9M | 16.05M | 37.85M | 51.26M | 349.71K | 239.61K |
| Cash & Short-Term Investments | 42.99M | 66M | 94.43M | 14.45M | 35.5M | 49.64M | 341.04K | 226.6K |
| Cash Only | 42.99M | 66M | 94.43M | 14.45M | 35.5M | 49.64M | 341.04K | 226.6K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 2.36M | 3.47M | 1.6M | 2.36M | 0 | 0 | 0 |
| Total Non-Current Assets | 315.29K | 140.07K | 230.78K | 15.52K | 112.28K | 50.39K | 117.63K | 33.94K |
| Property, Plant & Equipment | 315.29K | 140.07K | 230.78K | 15.52K | 79.53K | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 50.39K | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 32.75K | 0 | 117.63K | 33.94K |
| Total Assets | 46.13M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M | 467.34K | 273.55K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | -122.17% | -30.2% | 510.9% | -57.69% | -26% | 10878.25% | 70.84% | - |
| Total Current Liabilities | 7.88M | 8.02M | 2.75M | 4.19M | 3.21M | 3.03M | 9.55M | 24.11M |
| Accounts Payable | 3.29M | 2.53M | 1.45M | 2.38M | 936.33K | 1.83M | 2.71M | 2.07M |
| Days Payables Outstanding | 247.04K | - | - | - | - | - | - | - |
| Short-Term Debt | 167.47K | 0 | 0 | 0 | 0 | 0 | 5.88M | 21.84M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1.42M | 941.7K | 661.3K | 853.51K | 85.53K | 0 | 0 |
| Current Ratio | 5.81x | 8.52x | 35.62x | 3.83x | 11.80x | 16.90x | 0.04x | 0.01x |
| Quick Ratio | 5.81x | 8.52x | 35.62x | 3.83x | 11.80x | 16.90x | 0.04x | 0.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 77.52K | 0 | 112.06K | 0 | 0 | 0 | 7.84M | 126K |
| Long-Term Debt | 77.52K | 0 | 0 | 0 | 0 | 0 | 69.04K | 0 |
| Capital Lease Obligations | 21.22K | 0 | 112.06K | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 7.77M | 126K |
| Total Liabilities | 7.96M | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M | 17.39M | 24.23M |
| Total Debt | 244.99K | 112.06K | 219.38K | 0 | 55.08K | 0 | 5.95M | 21.84M |
| Net Debt | -42.75M | -65.88M | -94.21M | -14.45M | -35.44M | -49.64M | 5.61M | 21.62M |
| Debt / Equity | 0.01x | 0.00x | 0.00x | - | 0.00x | - | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.89x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -27.19x | -115.78x | -3.89x | -4.80x |
| Total Equity | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M | -16.92M | -23.96M |
| Equity Growth % | -145.64% | -36.52% | 702.51% | -65.85% | -28% | 385.28% | 29.38% | - |
| Book Value per Share | 0.40 | 0.64 | 1.63 | 0.74 | 2.18 | 17.03 | -1.54 | -2.19 |
| Total Shareholders' Equity | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M | -16.92M | -23.96M |
| Common Stock | 91.88K | 91.88K | 89.7K | 15.97K | 15.97K | 15.97K | 332 | 324 |
| Retained Earnings | -154.14M | -130.9M | -94.78M | -68.05M | -44.09M | -29.25M | -18.8M | -25.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CNTX stock.
As of 2025, Context Therapeutics Inc. (CNTX) had total assets of $68.5M including $68.4M in current assets.
Context Therapeutics Inc. (CNTX) carries total debt of $0.1M, offset by $66.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Context Therapeutics Inc. (CNTX) has total shareholders' equity (book value) of $60.5M ($0.64 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Context Therapeutics Inc. (CNTX) reported a current ratio of 8.52x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Clinical trial funding runway
Metrics are mathematically derived from official filings.
Cash Runway Amidst Operational Burn
According to recent SEC filings, Context Therapeutics maintains a cash position of $66 million as of 2025Q4, providing a critical liquidity buffer that supports ongoing clinical development while the company continues to operate without any recurring commercial revenue streams to offset its substantial quarterly research expenditures.
The current ratio of 8.52 in 2025Q4 reflects a strong short-term liquidity position, which is essential for a pre-revenue biotech firm managing high-cost clinical trials. Investors should monitor the rate of cash depletion, as the transition from 2024Q4's $94.4 million cash balance to current levels suggests a consistent burn rate that necessitates disciplined capital allocation.
Equity Erosion Through Accumulated Deficits
As reported in financial statements, the company's equity base has contracted to $60.5 million in 2025Q4, a trend primarily driven by the persistent accumulation of net losses which reached $130.9 million, reflecting the high cost of advancing the ONA-XR and CLDN6 bispecific antibody programs.
The steady decline in retained earnings highlights the structural challenge of funding long-term R&D without commercial product sales. While the lack of debt preserves equity value, the ongoing dilution risk remains a primary concern for shareholders as the company relies on equity markets to replenish its capital base.
Strategic Absence of Financial Leverage
Based on reported figures, Context Therapeutics maintains a virtually debt-free balance sheet, with total debt of only $112.1K in 2025Q4, which provides the firm with significant strategic flexibility and avoids the interest expense burdens that often constrain clinical-stage peers in high-interest-rate environments.
The minimal debt levels suggest that management has prioritized financial stability over aggressive, debt-funded expansion. This conservative capital structure is a distinct advantage, as it eliminates refinancing risk and allows the company to focus its limited resources entirely on clinical trial execution and pipeline development.
Hidden Risks in Asset Composition
As indicated by the provided financial data, the company's asset base is almost entirely composed of cash and cash equivalents, with negligible investments in property, plant, or equipment, which underscores the firm's reliance on external contract manufacturing rather than internal production capabilities.
The lack of tangible assets suggests that the company's value is almost exclusively tied to its intellectual property and clinical trial progress. This asset-light model is typical for the sector but implies that any failure in clinical data readouts could lead to a rapid and significant impairment of the company's perceived enterprise value.